Introduction {#Sec1}
============

During the past 10 years, a substantial number of articles have reported the survival of esophageal carcinoma (EC) patients with dysregulated microRNA (miRNA) expression^[@CR1]--[@CR96]^. As the twelfth origin of incident cases and the seventh major cause of cancer-related death all over the world^[@CR97]^, it contains two main types: esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). In the United States, EAC nowadays occupies about 7% of all EC cases. ESCC is the main subtype of EC among Asian patients. Although the treatment and prognosis of EC have been improved by multimodal therapies, the rate of 5-year overall survival (OS) remains poor^[@CR98]^.

It is well known that EC is a complex inherited disease that is characterized by altered expression levels of certain coding or non-coding genes. As the high-throughput analysis develops, an increasing number of cancer-related non-coding RNAs have been recognized^[@CR99]^. miRNAs, a class of small non-coding RNAs \<25 nucleotides in length, act as negative regulatory factors of gene expression by depressing translation or causing deadenylation-dependent degradation of target messenger RNAs (mRNAs)^[@CR100]^. They have been shown to be involved in various processes of tumor progression, including proliferation and metastasis of cancer cells^[@CR101]^. In particular, EC-related miRNAs have been proved to exert functional diversity via multiple biological processes.

Despite comprehensive research aimed at illuminating the molecular mechanisms in EC, there are still challenges facing the identification of prognostic biomarkers that are minimally invasive and sensitive. Therefore, it is crucial to develop prognostic cancer biomarkers that can be expediently and reliably applied in the clinical setting, improving the survival of EC patients.

Recently, an increasing amount of evidence indicates that miRNAs can act as possible biomarkers for cancer prognosis in clinical practice that is fairly encouraging and exciting^[@CR1]--[@CR96]^. However, there has not been a systematic review and meta-analysis to estimate the associations between miRNA expression and the survival of EC patients. Therefore, the current study aimed to identify that correlation by searching the recently published evidence regarding miRNAs as prognostic tools for EC in cancer tissues and in blood.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

The comprehensive online search about articles from four databases, PubMed, Web of Science, Embase, and Cochrane Database of Systematic Reviews, was performed by two independent authors (S.G. and Z.-Y.Z.). Subsequently, Y.Z. re-evaluated uncertain data. A comprehensive search was conducted employing the subject terms: "microRNA," "miRNA," "miR", and "esophageal carcinoma," "esophagus carcinoma," "oesophageal carcinoma." Of the four databases, there were 461 records after duplicates were removed. Subsequently, we excluded 335 records by titles and abstracts. For the remaining 126 records, 30 full-text articles were excluded. The details are shown in Fig. [1](#Fig1){ref-type="fig"}. The search deadline was April 12, 2018.Fig. 1Flow diagram of the literature search and selection

Inclusion criteria {#Sec4}
------------------

We came up with inclusion criteria for qualified articles that were analyzed by our full-text estimation: (1) articles concerning the pertinence between miRNA level and prognosis of EC patients; (2) the survival results that were estimated by OS; (3) full-text articles published in English.

Exclusion criteria {#Sec5}
------------------

Articles that were not satisfied with the aforementioned inclusion criteria, reviews, letters, or laboratory studies without raw data (Kaplan--Meier survival curves or HR with 95% CI) were excluded. Articles of non-dichotomous miRNA expression levels and frequency of studies assessing prognostic value of miRNAs equal to 1 were also excluded. If more than one paper had been published on the identical study cohort, only the most well-rounded investigation was selected for the current study. Besides, if both of the univariate and multivariate outcomes were reported, only the latter were chosen, since they were adjusted for confounding factors.

Quality assessment {#Sec6}
------------------

S.G. and Z.-Y.Z. confirmed all eligible investigations that analyzed the prognostic value of miRNAs in EC, and Y.Z. reassessed uncertain data. Quality assessment for each study was done using modified Newcastle--Ottawa Scale (NOS)^[@CR102]^. NOS scores were calculated on the basis of selection, comparability, and outcome. Papers with NOS scores ≥6 were considered high-quality articles^[@CR103]^.

Study selection {#Sec7}
---------------

A flow diagram with details of the study selection process was presented in Fig. [1](#Fig1){ref-type="fig"}.

Study frequency {#Sec8}
---------------

The frequency of studies estimating the prognostic value of miRNAs in EC was shown in Supplementary Tables [1](#MOESM9){ref-type="media"} (tissue) and [2](#MOESM10){ref-type="media"} (blood), including the miRNA names, the frequency of studied miRNAs, and the references. In addition, frequency of strong miRNAs is shown in Table [1](#Tab1){ref-type="table"}.Table 1Frequency of strong microRNAs studied in esophageal carcinomaTissueBloodmiR*FR*miR*FR*133a232.3321287.89133b213.34138235.36203249.50655275.76*F* frequency of the studied microRNAs, *R* reference

Study characteristics {#Sec9}
---------------------

The basic information of the included articles is comprehensively detailed in Supplementary Table [3](#MOESM11){ref-type="media"}. If the data were not provided in the text but only as Kaplan--Meier survival curves, the data were extracted from the graphical survival plots, and estimations of the HR with 95% CI were then performed using a previously described method^[@CR104]^ with the software Engauge Digitizer version 4.1.

Statistical analysis {#Sec10}
--------------------

All analyses were conducted using Stata version 13.0 (StataCorp, College Station, TX, USA). OS was the main and only reference standard for prognostic value of miRNAs. The HR was considered significant at the *P* \< 0.05 level if the 95% CI did not include the value 1. In addition, a single miRNA was regarded as the strong candidate if its HR was ≥2. Owing to different types of samples (formalin-fixed, paraffin-embedded, frozen tissue, plasma, and serum) from EC patients at different stages, cutoff values, and miRNA methods in individual studies, random-effects models were more appropriate than fixed-effects models for most of the analyses. Accordingly, the former were employed in the current meta-analysis. Publication bias was estimated using Begg's funnel plot. A two-tailed *P* value \<0.05 was considered significant. A sensitivity analysis (influence analysis) was carried out to test how sensitive the combined effect size was to the removal of individual investigations. If the point assessment was outside of the 95% CI of the pooled effect size after it was removed from the analysis, an individual study was considered to have excessive influence.

Results {#Sec11}
=======

Meta-analysis {#Sec12}
-------------

A summary of the HR with 95% CI evaluated from the whole combined analysis for all the miRNAs is shown in Table [2](#Tab2){ref-type="table"}. The forest plots, Begg's funnel plots, and sensitivity analyses are shown in Supplementary Figures [1](#MOESM1){ref-type="media"}--[8](#MOESM8){ref-type="media"} according to the logic sequencing of miRNA names. For the included 96 studies, 52 were excluded because the frequency of them evaluating prognostic value of miRNA was equal to 1^[@CR3],[@CR4],[@CR16],[@CR18]--[@CR23],[@CR26],[@CR30],[@CR31],[@CR39]--[@CR46],[@CR48],[@CR53],[@CR54],[@CR56],[@CR60],[@CR61],[@CR64]--[@CR74],[@CR77]--[@CR86],[@CR92]--[@CR96]^. In addition, although one article reported OS results about miR-193a-5p, it was excluded because it had non-dichotomous miRNA expression value^[@CR105]^. The mean NOS score of the included researches was 6.5 (4.0--8.0), indicating that the quality of them was adequate (Supplementary Table [4](#MOESM12){ref-type="media"}).Table 2HR with 95% CI of microRNA expression in esophageal carcinomaSampleMicroRNA*N*Included articlesHR95% CIFigure*P* valueHeterogeneity (Higgins *I*^2^ statistic)Total patientsTissueLow let-7g2^[@CR1],\ [@CR2]^1.270.66--2.45Supplementary Figure [1](#MOESM1){ref-type="media"}0.47*I*^2^ = 58.6%, *P* = 0.12197TissueHigh miR-92^[@CR2],\ [@CR5]^1.070.45--2.57Supplementary Figure [1](#MOESM1){ref-type="media"}0.88*I*^2^ = 72.8%, *P* = 0.06342TissueHigh miR-2110^[@CR1],\ [@CR2],\ [@CR7]--\ [@CR14]^1.631.26--2.11Supplementary Figure [1](#MOESM1){ref-type="media"}\<0.01*I*^2^ = 23.8%, *P* = 0.221071TissueHigh miR-26a2^[@CR15],\ [@CR17]^1.090.19--6.39Supplementary Figure [2](#MOESM2){ref-type="media"}0.92*I*^2^ = 47.5%, *P* = 0.17116TissueLow miR-34a2^[@CR2],\ [@CR24]^1.870.88--3.99Supplementary Figure [2](#MOESM2){ref-type="media"}0.11*I*^2^ = 45.4%, *P* = 0.18210TissueHigh miR-92a2^[@CR6],\ [@CR25]^1.470.64--3.34Supplementary Figure [2](#MOESM2){ref-type="media"}0.36*I*^2^ = 54.4%, *P* = 0.14170TissueLow miR-1004^[@CR13],\ [@CR27]--\ [@CR29]^2.120.86--5.21Supplementary Figure [2](#MOESM2){ref-type="media"}0.10*I*^2^ = 73.2%, *P* = 0.01410TissueLow miR-133a2^[@CR32],\ [@CR33]^2.481.50--4.12Fig. [2](#Fig2){ref-type="fig"}\<0.01*I*^2^ = 0.0%, *P* = 0.76210TissueLow miR-133b2^[@CR13],\ [@CR34]^2.151.27--3.62Fig. [2](#Fig2){ref-type="fig"}\<0.01*I*^2^ = 0.0%, *P* = 0.97265TissueLow miR-1382^[@CR35],\ [@CR36]^2.271.68--3.08Fig. [2](#Fig2){ref-type="fig"}\<0.01*I*^2^ = 0.0%, *P* = 0.33333TissueHigh miR-143--3p2^[@CR37],\ [@CR38]^1.120.13--9.33Supplementary Figure [2](#MOESM2){ref-type="media"}0.92*I*^2^ = 95.4%, *P* \< 0.01199TissueHigh miR-1452^[@CR1],\ [@CR29]^0.850.27--2.66Supplementary Figure [2](#MOESM2){ref-type="media"}0.79*I*^2^ = 73.1%, *P* = 0.05143TissueHigh miR-1552^[@CR1],\ [@CR13]^1.170.64--2.14Supplementary Figure [3](#MOESM3){ref-type="media"}0.61*I*^2^ = 47.6%, *P* = 0.17283TissueHigh miR-200a2^[@CR2],\ [@CR47]^0.710.19--2.60Supplementary Figure [3](#MOESM3){ref-type="media"}0.60*I*^2^ = 78.6%, *P* = 0.03187TissueLow miR-2032^[@CR49],\ [@CR50]^2.831.35--5.95Fig. [2](#Fig2){ref-type="fig"}\<0.01*I*^2^ = 0.0%, *P* = 0.4070TissueHigh miR-2052^[@CR51],\ [@CR52]^0.750.09--6.45Supplementary Figure [3](#MOESM3){ref-type="media"}0.79*I*^2^ = 72.4%, *P* = 0.0657TissueHigh miR-2232^[@CR13],\ [@CR55]^1.130.25--5.03Supplementary Figure [3](#MOESM3){ref-type="media"}0.87*I*^2^ = 89.5%, *P* \< 0.01294TissueLow miR-3756^[@CR7],\ [@CR10],\ [@CR11],\ [@CR57]--\ [@CR59]^1.641.05--2.58Supplementary Figure [3](#MOESM3){ref-type="media"}0.03*I*^2^ = 64.8%, *P* \< 0.01729TissueHigh miR-455--3p2^[@CR62],\ [@CR63]^0.670.10--4.48Supplementary Figure [3](#MOESM3){ref-type="media"}0.68*I*^2^ = 93.6%, *P* \< 0.01326TissueLow miR-6552^[@CR75],\ [@CR76]^2.661.16--6.12Fig. [2](#Fig2){ref-type="fig"}0.02*I*^2^ = 0.0%, *P* = 0.9763BloodLow miR-162^[@CR87],\ [@CR88]^1.230.14--10.86Supplementary Figure [4](#MOESM4){ref-type="media"}0.86*I*^2^ = 90.3%, *P* \< 0.0162BloodHigh miR-212^[@CR87],\ [@CR89]^2.191.31--3.68Fig. [2](#Fig2){ref-type="fig"}\<0.01*I*^2^ = 0.0%, *P* = 0.79164BloodHigh miR-252^[@CR90],\ [@CR91]^1.750.56--5.54Supplementary Figure [4](#MOESM4){ref-type="media"}0.34*I*^2^ = 67.2%, *P* = 0.08257BloodHigh miR-2232^[@CR90],\ [@CR91]^1.621.12--2.34Supplementary Figure [4](#MOESM4){ref-type="media"}0.01*I*^2^ = 0.0%, *P* = 0.50257BloodLow miR-3753^[@CR87],\ [@CR89],\ [@CR91]^1.440.93--2.22Supplementary Figure [4](#MOESM4){ref-type="media"}0.10*I*^2^ = 29.1%, *P* = 0.24358*N* number of the included articles, *HR* hazard ratio, *CI* confidence interval

Tissue-based high miR-21 and low miR-133a, miR-133b, miR-138, miR-203, miR-375, and miR-655 levels predict poor OS {#Sec13}
------------------------------------------------------------------------------------------------------------------

Ten studies^[@CR1],[@CR2],[@CR7]--[@CR14]^ analyzed the connections between high tissue miR-21 levels and OS, suggesting that EC patients with high tissue miR-21 levels had significantly worse OS than those with low levels (HR = 1.63, 95% CI = 1.26--2.11, *P* \< 0.01, Supplementary Figure [1](#MOESM1){ref-type="media"}).

Two studies^[@CR32],[@CR33]^ reported the associations between low tissue miR-133a levels and OS, indicating that EC patients with low tissue miR-133a levels had significantly shorter OS than those with high levels (HR = 2.48, 95% CI = 1.50--4.12, *P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Forest plot of pooled analyses of OS in association with tissue expression levels of low miR-133a, miR-133b, miR-138, miR-203, and miR-605 and blood expression levels of high miR-21

Two studies^[@CR13],[@CR34]^ covered the relationship between low tissue miR-133b levels and OS, showing that EC patients with low tissue miR-133b levels had significantly poorer OS than those with high levels (HR = 2.15, 95% CI = 1.27--3.62, *P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}).

Two studies^[@CR35],[@CR36]^ focused on the pertinence between low tissue miR-138 levels and OS, suggesting that EC patients with low tissue miR-138 levels had significantly worse OS than those with high levels (HR = 2.27, 95% CI = 1.68--3.08, *P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}).

Two studies^[@CR49],[@CR50]^ stressed the correlations between low tissue miR-203 levels and OS, indicating that EC patients with high tissue miR-203 levels had significantly shorter OS than those with low levels (HR = 2.83, 95% CI = 1.35--5.95, *P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}).

Six studies^[@CR7],[@CR10],[@CR11],[@CR57]--[@CR59]^ emphasized the relevance between low tissue miR-375 levels and OS, showing that EC patients with low tissue miR-375 levels had significantly poorer OS than those with high levels (HR = 1.64, 95% CI = 1.05--2.58, *P* = 0.03, Supplementary Figure [3](#MOESM3){ref-type="media"}).

Two studies^[@CR75],[@CR76]^ paid attention to the relation between low tissue miR-655 levels and OS, suggesting that EC patients with low tissue miR-655 levels had significantly worse OS than those with high levels (HR = 2.66, 95% CI = 1.16--6.12, *P* = 0.02, Fig. [2](#Fig2){ref-type="fig"}).

Blood-based high miR-21 and miR-223 levels predict poor OS {#Sec14}
----------------------------------------------------------

Two studies^[@CR87],[@CR89]^ analyzed the connections between high blood miR-21 levels and OS, suggesting that EC patients with high blood miR-21 levels had significantly worse OS than those with low levels (HR = 2.19, 95% CI = 1.31--3.68, *P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}).

Two studies^[@CR90],[@CR91]^ reported the associations between low blood miR-223 levels and OS, indicating that EC patients with low blood miR-223 levels had significantly shorter OS than those with high levels (HR = 1.62, 95% CI = 1.12--2.34, *P* = 0.01, Supplementary Figure [4](#MOESM4){ref-type="media"}).

Publication bias {#Sec15}
----------------

Begg's funnel plot was used to evaluate publication bias in the OS of EC patients with high tissue miR-21 levels (Supplementary Figure [5](#MOESM5){ref-type="media"}). The results showed that the *P* value was 0.33, indicating the absence of a publication bias.

Begg's funnel plot was used to evaluate publication bias in the OS of EC patients with low tissue miR-375 levels (Supplementary Figure [6](#MOESM6){ref-type="media"}). The results showed that the *P* value was 0.73, indicating the absence of a publication bias.

Sensitivity analysis {#Sec16}
--------------------

The sensitivity analysis was applied to evaluate whether any individual study had excessive influence in the OS of EC patients with high tissue miR-21 levels (Supplementary Figure [7](#MOESM7){ref-type="media"}). The outcomes showed that no single investigation significantly influenced the merged HR and 95% CI.

The sensitivity analysis was applied to evaluate whether any individual study had excessive influence in the OS of EC patients with low tissue miR-375 levels (Supplementary Figure [8](#MOESM8){ref-type="media"}). The outcomes showed that no single investigation significantly influenced the merged HR and 95% CI.

Discussion {#Sec17}
==========

Primary discoveries {#Sec18}
-------------------

The present meta-analysis included 44 articles published in English that included 22 miRNAs and 4310 patients. miR-21 is the most studied miRNA, and EC patients with high tissue miR-21 levels have significantly shorter OS times than those with low levels. Similarly, high blood miR-21 levels have a significantly prognostic value for OS. In addition, some other miRNAs have significantly prognostic value for EC, including tissue miR-133a, miR-133b, miR-138, miR-203, miR-375, and miR-655 and blood miR-223. Among them, the tissue miR-133a, miR-133b, miR-138, miR-203, and miR-655 levels and the blood miR-21 level are strong biomarkers of prognosis in EC.

Molecular mechanisms of the studied miRNAs {#Sec19}
------------------------------------------

Furthermore, a summary of the 22 miRNAs with altered levels, including their potential targets and pathways, is presented in Fig. [3](#Fig3){ref-type="fig"}. Several miRNAs were not marked with up or down arrows since either they were not reported in the original articles or inconsistent expression levels of them were shown in the papers about the single miRNA. In general, Fig. [3](#Fig3){ref-type="fig"} can help us better understand the functions of miRNAs in EC. As the strong candidate biomarkers of EC, tissue miR-133a, miR-138, and miR-203 were with downregulated expression and blood miR-21 was with upregulated expression. In addition, metadherin was the target of miR-21. miR-138 downregulation caused lipid raft formation by upregulating flotillin 1, flotillin 2, and caveolin-1 and promoted invasion of ESCC cells as well as sustained nuclear factor-κB activity. Furthermore, pituitary tumor-transforming 1, zinc finger E-box binding homeobox 1, and transforming growth factor beta receptor 2 were identified as direct targets of miR-655, overexpression of which could suppress migration and invasion of EC9706 and KYSE150 cells.Fig. 3Summary of microRNAs with altered expression, potential targets, and pathways entered in this study. E-cadherin cadherin 1, type 1, E-cadherin (epithelial), PDCD4 programmed cell death 4, MTDH metadherin, CDH1 cadherin 1, mTOR mechanistic target of rapamycin kinase, FLOT1 flotillin 1, FLOT2 flotillin 2, PTEN phosphatase and tensin homolog, MMP10 matrix metallopeptidase 10, FBXW7 F-box and WD repeat domain containing 7, IGF1R insulin like growth factor 1 receptor, FAM83F family with sequence similarity 83 member F, DKK3 dickkopf WNT signaling pathway inhibitor 3, GSK3β glycogen synthase kinase 3 beta, Smurf2 SMAD specific E3 ubiquitin protein ligase 2, PPM1A protein phosphatase, Mg2+/Mn2+ dependent 1A, PTTG1 pituitary tumor-transforming 1, ZEB1 zinc finger E-box binding homeobox 1, TGFBR2 transforming growth factor beta receptor 2, NF-kB nuclear factor-kappaB, PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta, AKT AKT serine/threonine kinase 1, TGF-β transforming growth factor-β

Strengths of the meta-analysis {#Sec20}
------------------------------

This work had certain strengths: (1) we searched for and identified almost all articles with survival outcomes in EC patients with altered miRNA levels. In addition, the current expression profiles of miRNAs were distinctly listed in Supplementary Tables [1](#MOESM9){ref-type="media"} and [2](#MOESM10){ref-type="media"} by distinguishing miRNA names and the kinds of detected samples; (2) most of our included articles had large sample sizes (≥30, except 4 studies \[refs. ^[@CR49],[@CR51],[@CR75],[@CR88]^\]), strengthening and broadening the applicability of the prognostic results to EC patients; (3) combined analyses for most of miRNAs with significantly prognostic value indicated low heterogeneity (*I*^2^ ≤ 50, except tissue miR-375).

Limitations {#Sec21}
-----------

The following limitations of our meta-analysis should be noted: (1) there were multiple variables in the present study, including different types of samples (formalin-fixed, paraffin-embedded, frozen tissue, plasma, and serum) from EC patients at different stages, cutoff values, and miRNA methods, among which the sample type and cutoffs were major limitations; (2) we only included articles published in English, probably excluding potential studies published in other languages about miRNA expression and prognosis in EC patients; (3) we only included studies estimating OS, possibly excluding potential researches with prognosis with other survival outcomes, such as cause-specific survival, disease-free survival, recurrence-free survival, progression-free survival, and metastasis-free survival; (4) although the mean NOS score of the included researches was 6.5, which indicated that the quality of them was adequate, we still could not ignore the low scores among them (the NOS scores were 4--5).

Implications for future clinical and basic research {#Sec22}
---------------------------------------------------

It was worth noting that this meta-analysis was the first systematic estimation of the associations between dysregulated miRNA levels and the prognosis of EC patients. There were implications for future clinical and basic investigations: (1) combined detection of multiple miRNA levels could be used by clinical workers and other health-care providers, which might greatly augment the ability to estimate survival time of EC patients so that timely treatment could be provided; (2) the present research advances and trends regarding miRNA levels and the prognosis of EC patients could be clearly obtained by basic researchers in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Meanwhile, the molecular mechanisms of miRNAs could be seen in Fig. [3](#Fig3){ref-type="fig"}, which could be referred to at the same time as Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}; (3) some conflicting results regarding the prognostic value of miRNAs might be resolved based on this work.

Conclusions {#Sec23}
-----------

In conclusion, the tissue expression levels of miR-21, miR-133a, miR-133b, miR-138, miR-203, miR-375, and miR-655 and the blood expression levels of miR-21 and miR-223 demonstrate significant prognostic value. Among them, the expression levels of miR-133a, miR-133b, miR-138, miR-203, and miR-655 in tissue, and the expression level of miR-21 in blood are potential prognostic candidates for predicting OS in EC.

Study Highlights {#Sec119}
================

What is current knowledge {#Sec525}
-------------------------

Increasing evidence indicates that microRNAs can act as possible biomarkers for cancer prognosis in clinical practice.However, there has not been a systematic review and meta-analysis to estimate the associations between microRNA expression and the survival of esophageal carcinoma patients.

What is new here {#Sec2551}
----------------

This work is the first systematic review and meta-analysis about prognostic value of microRNAs in esophageal carcinoma.Several microRNAs suggest significantly prognostic value and are potential prognostic candidates for predicting overall survival for esophageal carcinoma.

Translational impact {#Sec02551}
--------------------

Combined detection of multiple microRNA levels could be used by clinical workers and other healthcare providers, which might greatly augment the ability to estimate survival time of esophageal carcinoma patients so that timely treatment could be provided.
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